

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ANNOUNCEMENT MADE PURSUANT TO RULE 13.51B(2) OF THE LISTING RULES**

This announcement is made by China Merchants Land Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51B(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to an update of information of Dr. Wong Wing Kuen, Albert (“**Dr. Wong**”), an independent non-executive director of the Company, set out under Rule 13.51(2)(1) of the Listing Rules.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company was notified by Dr. Wong that Dexin China Holdings Company Limited (“**Dexin China**”), an independent third party unrelated to the Group, was ordered to be wound up by the High Court of The Hong Kong Special Administrative Region (the “**High Court**”) on 11 June 2024 (the “**Winding-up Order**”) and the Official Receiver was appointed as the provisional liquidator of Dexin China. Dr. Wong has been an independent non-executive director of Dexin China since 11 January 2019 and has tendered his resignation letter to Dexin China on 11 June 2024 to resign as the independent non-executive director of Dexin China, with effect from 11 June 2024. For further information regarding the Winding-up Order and the proceedings in relation to Dexin China, please refer to the respective announcements of Dexin China dated 21 March 2024, 5 June 2024 and 12 June 2024 published on the website of the Stock Exchange.

Based on publicly available information, Dexin China is a company incorporated in the Cayman Islands with limited liability, and Dexin China and its subsidiaries are primarily engaged in the property development and construction services, property investment and hotel operations in the People’s Republic of China. The shares of Dexin China are listed on the Main Board of the Stock Exchange (stock code: 2019) and have been suspended since 11 June 2024 and up to the date of this announcement.

Dr. Wong has confirmed that he is not a party to the winding up proceedings of Dexin China and is not aware of any current or potential claim that has been or will be made against him as a result of such proceedings.

As the Winding-up Order was made against Dexin China within 12 months of Dr. Wong's cessation as an independent non-executive director of Dexin China, it constitutes an event required to be disclosed by the Company pursuant to Rules 13.51(2)(1) and 13.51B(2) of the Listing Rules.

The Board has no further information on the Winding-up Order other than those set out above which is based on the information supplied by Dr. Wong and publicly available information. The Board is not in a position to express any opinion on the matters relating to the Winding-up Order. As the Winding-up Order did not involve the Group, the Board is of the opinion that it does not and will not have any impact on the businesses and operations of the Group.

As the underlying claims of the Winding-up Order did not involve mismanagement or integrity issue on the part of Dr. Wong, the Board is of the opinion that the Winding-up Order does not and will not affect Dr. Wong's suitability and ability to discharge his duties as an independent non-executive Director, the chairman of the audit committee, and a member of the remuneration committee of the Company.

This announcement is made by the Company to report the change of information in relation to Dr. Wong in compliance with the requirements under Rule 13.51B(2) of the Listing Rules. Dr. Wong has confirmed that save as disclosed in this announcement, there are no other matters in relation to him which are required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and he is not aware of any other matters that need to be brought to the attention of the Company and its shareholders.

By order of the Board  
**China Merchants Land Limited**  
**JIANG Tiefeng**  
*Chairman*

Hong Kong, 17 June 2024

*As at the date of this announcement, the Board comprises Mr. JIANG Tiefeng, Mr. HUANG Junlong and Mr. Li Yao as non-executive Directors; Dr. SO Shu Fai, Mr. WONG King Yuen and Ms. CHEN Yan as executive Directors and Dr. WONG Wing Kuen, Albert, Ms. CHEN Yanping, Dr. SHI Xinping and Mr. IP Man Ki Ryan as independent non-executive Directors.*